Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | TYMS | P04818 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688203 | 1.00 | PARP1 (1.00) | PARP1CA12CA9ALDH1A1KDM4E | |
| SCHEMBL27638376 | 0.82 | CA12 (0.70) | PARP1CA12CA9ALDH1A1KDM4E | |
| SCHEMBL20340677 | 0.80 | PARP1 (0.66) | PARP1CA12CA9AURKAKDR | |
| SCHEMBL14896 | 0.77 | CA12 (1.00) | PARP1CA12CA9AURKAKDR | |
| SCHEMBL4818277 | 0.77 | CA12 (1.00) | PARP1CA12CA9AURKAKDR | |
| SCHEMBL29355184 | 0.77 | CA12 (1.00) | PARP1CA12CA9AURKAKDR | |
| SCHEMBL11354047 | 0.75 | CA12 (0.95) | PARP1CA12CA9AURKAKDR | |
| Water SCHEMBL19462837 | 0.75 | CA12 (0.95) | PARP1CA12CA9AURKAKDR | |
| Hydrochloric Acid SCHEMBL5046932 | 0.75 | CA12 (0.95) | PARP1CA12CA9AURKAKDR | |
| Water SCHEMBL19462703 | 0.75 | CA12 (0.95) | PARP1CA12CA9AURKAKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103917369-B | Single-layer carbon dioxide barrier PET bottle | 普莱斯提派克包装公司 | 2020-06-12 | — | — | CN | claimed |
| US-20190169425-A1 | MONOLAYER CARBON DIOXIDE BARRIER PET BOTTLES | PLASTIPAK PACKAGING INC (US) | 2019-06-06 | — | — | US | claimed |
| US-10011714-B2 | Monolayer carbon dioxide barrier PET bottles | PLASTIPAK PACKAGING, INC. (US) | 2018-07-03 | — | — | US | claimed |
| EP-2750890-B1 | MONOLAYER CARBON DIOXIDE BARRIER PET BOTTLES | PLASTIPAK PACKAGING INC (US) | 2018-06-06 | — | — | EP | claimed |
| US-20130231422-A1 | MONOLAYER CARBON DIOXIDE BARRIER PET BOTTLES | WELLS FARGO BANK, N.A., AS ADMINISTRATIVE AGENT | 2013-09-05 | — | — | US | claimed |
| EP-1931637-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2008-06-18 | — | — | EP | claimed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | claimed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-20250381221-A1 | Compositions and Methods for Treating Cancer | IN8BIO INC (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | LANTERN PHARMA INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20220339179-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2022-10-27 | — | — | US | disclosed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | KUDOS PHARMACEUTICALS LIMITED | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | PARP1 1/4885CA12 2721/4885CA9 1273/4885 |
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | PARP1 2/4885CA12 3869/4885CA9 3017/4885 |
| US-20240299322-A1 | TREATING CANCERS WITH COMBINATIONS OF PARP INHIBITOR AND ACYLFULVENES | PARP1, PARP2, PARP11 | PARP1 1/4885CA12 3923/4885CA9 1719/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | PARP1 4/4885CA12 4641/4885CA9 3761/4885 |
| US-20050227919-A1 | DNA damage repair inhibitors for the treatment of cancer | MRE11, ERCC4, PARP2 | PARP1 7/4885CA12 4594/4885CA9 3694/4885 |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | PARP1 3414/4885CA12 1700/4885CA9 3754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.